Cost-effectiveness analysis of first-line treatments for recurrent or metastatic head and neck cancer in China: an economic evaluation based on network meta-analysis.

ABSTRACT:

Background

Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a common pathological type of head and neck tumors, imposing a huge disease burden in China. This study evaluated the cost-effectiveness of three first-line treatment regimens for R/M HNSCC approved in China from the perspective of Chinese payers, including cetuximab plus chemotherapy, pembrolizumab as monotherapy or in combination with chemotherapy, and finotonlimab plus chemotherapy, aiming to provide reference for decision-making.

Methods

Based on the data from three randomized controlled trials: KEYNOTE-048 (NCT02358031), CHANGE-2 (NCT02383966), and the finotonlimab trial (NCT04146402), we conducted a network meta-analysis and employed partitioned survival model (PSM) to indirectly ev

SUBMITTER: Liu F 

PROVIDER: S-EPMC12517582 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature